
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) drives significant morbidity and mortality. Diagnosis relies on HRCT and PFTs, but biomarkers like CCL18, KL-6, IL-6, and CRP enhance risk stratification. Immunosuppressants and antifibrotics form the treatment backbone. Innovative options like stem cell transplants and CAR T-cell therapy show promise. Adaptive clinical trials are essential to tackle disease heterogeneity and improve personalized care.
Like
Save
Share